The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Oops, CEO Welcome needs updating! https://avacta.com/investors/ceo-welcome/
Long term holder here who rarely posts as I have little insight to share that is not already uncovered by other investors either on this board or twitter. I do, however, read this board daily just in case there is a small amount of new information or insight regarding my Avacta investment. As we all know, sadly, 95% of posts (and I'm not exaggerating btw) are pure dross offering no insight whatsoever. Unfortunately, both PL75 and NYsize, fall under the dross category with neither of them ever and I mean EVER offering up snippets of research or interesting discoveries about Avacta. Could you both please stop posting unless you have some insight to share. Follow my example and stop wasting your time and everyone else's time reading the rubbish you post. Get a life! Cheers.
The new shareholding was estimated to be 25% in one of the company's presentation, but the actual shareholding % has yet to be announced.
The Avacta team will not be presenting, as no RNS has been released to confirm their participation.
What goes on between Avacta and the FDA stays between Avacta and the FDA. The FDA approval will not release the P1a data. My money is on the data being released at the same time as a partnership/licence deal is announced.
Just found out that Avacta is listed on the Nasdaq stock exchange. It was listed on the Nasdaq OTCQX market in October 2021.
The OTCQX market is a valuable resource for companies and investors alike. It provides companies with a way to access the U.S. market without having to go through the expense and complexity of listing on a major exchange, and it provides investors with access to a wide range of established, international companies.
So, it looks like Avacta took this option to access US investors rather than an expensive full listing.
The assets refers to affimer and precision assets, as in 2 assets. Not multiple precision assets.
Not long to wait for the release of the P1A data, and I can’t wait to see it. But does anyone know why the data is being published before the completion of the study? My guess is that it is being published early to attract partnerships and/or licence agreements, thus securing funding sooner rather than later. Am I right?
Whenever there is some share price action, I try and get to the bottom of the movement. There has been some speculation that the recent increase in volume and increase in share price is due to the imminent C6 update. However, I believe this to be fake news. The reason is due to covid raising it's ugly head once more.
Why do I think this? Well, all I had to do was check how other diagnostic companies fared last week, and lo and behold, they also experienced increased volume and share prices. Take a look at NCYT and BVC as a couple of examples.
Intravenously
Thompi, it's not extremely likely C6 is underway, it IS underway. Please try and keep up.
Avacta will be sold for billions long before P2 starts, mate!
I wish you was as smart as him too!
ditto
nice find, Vegas. how are you old boy?
good pick-up bbtablet, I noticed that as soon as I posted but unfortunately there's no option to delete a post (if there was I would delete all NDN's posts!)
ooh this is awkward, MrRipley. You corrected demolition123's grammar 'It’s their not there.' Actually it should have been 'they're'!
CrudeTrader, you do know here's a shortage of LFTs, right? We'll sell as many as we can make. How many we can make is the key question.
Let it go, NDN71. What's done is done. The future remains very bright. Let's concentrate on the future, son.
and thanks for spamming this BB, ysc